!!Stephanie Cragg - Curriculum Vitae
\\
__EDUCATION__
\\
*1993 MA Natural Sciences (Pharmacology), University of Cambridge, UK\\
*1996 DPhil Pharmacology, University of Oxford, UK
\\
__ACADEMIC POSTS and PRIZE FELLOWSHIPS__
\\
*2014 Professor of Neuroscience, University of Oxford, UK\\
*2006 Tutorial Fellow in Preclinical Medicine, Christ Church, Oxford  \\
*2006 - 2014 Associate Professor in Biomedical Sciences, Oxford\\
*2004 - 2006 Paton Fellow, Department of Pharmacology, Oxford\\
*2001 - 2004 Beit Memorial Prize Research Fellowship, Oxford\\
*1999 - 2002 E.P. Abraham Research Fellowship, Oxford	 \\
*1996 - 1999 E.P. Abraham Junior Research Fellowship, Oxford\\
*1995 - 1999 Visiting Scientist, New York University, and University of North Carolina at Chapel Hill\\
*1995 - 1998 Mary Goodger Scholarship, University of Oxford
\\
__MAJOR CONTRIBUTIONS TO SCIENCE__\\
\\
[Published works|https://www.ncbi.nlm.nih.gov/myncbi/stephanie.cragg.1/bibliography/public] \\
\\
__1997 - 2006 Somatodendritic dopamine release:__ \\
\\
First real-time characterization of somatodendritic release of dopamine from midbrain neurons and regulatory mechanisms (e.g. Cragg et al 1997 J Neurophysiol; Cragg & Greenfield 1997 J Neurosci).\\
\\
__2001 - 2008 Dopamine as a volume transmitter: __\\
\\
Defined the concept of ‘volume’ or extrasynaptic transmission by dopamine (e.g. Cragg et al 2001 J Neurophysiol; Cragg and Rice 2004 Trends Neurosci)\\
\\
__2012 - ongoing Dysregulation of neurotransmission as a prodromal signature of Parkinson’s disease:__\\
\\
In diverse rodent models of Parkinson’s and our work in Oxford Parkinson’s Disease Centre, we established that signatures of dysregulation of neurotransmission precede degeneration (e.g. Janezic et al 2013 PNAS; Roberts et al 2020 Nat Commun) and can be rescued (Brimblecombe et al in review).\\
\\
__2003 - ongoing 	Axonal integration shapes dopamine function:__ \\
\\
Field leaders in identifying circuits and mechanisms in axons that govern dopamine transmission including partner neuromodulators (ACh, GABA, adenosine), ion channels, transporters, Parkinson’s associated proteins, and non-neuronal mechanisms, establishing astrocytes as key partners to striatal circuits (e.g. Cragg 2003 J Neurosci; Rice and Cragg 2004 Nat Neurosci; Zhang et al 2018 Neuron; Condon et al 2019 Nat Commun; Roberts et al 2020 Nat Commun; Stedehouder et al 2024 Nat Commun; Zhang et al 2025 Nat Neurosci). \\
\\
__EXTERNAL LEADERSHIP ROLES (last 10y)__
\\
*2024 - 2026 President, International Society for Monitoring Molecules in Neuroscience (MMiN)\\
*2025 Editor, The Handbook of Dopamine (Elsevier)\\
*2022 Founding Member and Inaugural Officer, the Dopamine Society\\
*2021 Chair, Neuromodulation Theme, ASAP Collaborative Research Network \\
*2021 Editorial Board Member, Addiction Neuroscience \\
*2019 - 2024 College of Experts, Parkinson’s UK\\
*2018 Conference Chair, 17th International Conference for MMiN\\
*2017 - 2023 Associate Editor, npj Parkinson’s Disease\\
*2010 - 2021 Co-Founder and Theme Co-Director, Oxford Parkinson’s Disease Centre\\
*2016 Advisory Board, ACS Chemical Neuroscience\\
*2015 Editorial Board, npj Parkinson’s Disease\\ \\[{ALLOW view All}][{ALLOW edit scragg}][{ALLOW upload scragg}][{ALLOW comment All}]